Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD   Taher A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite

Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670

By  

Current Medicinal Chemistry, Vol. 10, Iss. 12, 2003-06 ,pp. : 1065-1076

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

By  

Current Medicinal Chemistry, Vol. 12, Iss. 23, 2005-11 ,pp. : 2663-2681

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Iron Chelation in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 10, Iss. 12, 2003-06 ,pp. : 1021-1034

Bentham Science Publishers

Access to resources Recommend Favorite

Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3222-3234

Bentham Science Publishers

Access to resources Recommend Favorite